Boston Scientific Corporation (NYSE:BSX) EVP Joseph Michael Fitzgerald sold 85,227 shares of the company’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $26.48, for a total value of $2,256,810.96. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Boston Scientific Corporation (NYSE BSX) traded down $1.12 during trading on Thursday, hitting $25.20. The stock had a trading volume of 12,589,094 shares, compared to its average volume of 10,026,955. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. The company has a market cap of $36,691.80, a price-to-earnings ratio of 367.71, a PEG ratio of 1.94 and a beta of 0.81. Boston Scientific Corporation has a 12-month low of $23.29 and a 12-month high of $29.93.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Thursday, February 1st. The medical equipment provider reported $0.34 EPS for the quarter, meeting the consensus estimate of $0.34. The firm had revenue of $2.41 billion for the quarter, compared to analyst estimates of $2.39 billion. Boston Scientific had a return on equity of 24.04% and a net margin of 1.15%. The company’s revenue was up 9.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.30 EPS. analysts expect that Boston Scientific Corporation will post 1.37 EPS for the current year.

A number of equities analysts have weighed in on the company. Jefferies Group restated a “neutral” rating on shares of Boston Scientific in a research note on Friday, February 2nd. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “hold” rating in a research note on Tuesday, January 30th. TheStreet upgraded Boston Scientific from a “c+” rating to a “b” rating in a research note on Thursday, January 18th. Canaccord Genuity restated a “buy” rating on shares of Boston Scientific in a research note on Wednesday, January 17th. Finally, Needham & Company LLC restated a “buy” rating and issued a $32.00 target price on shares of Boston Scientific in a research note on Tuesday, January 16th. One research analyst has rated the stock with a sell rating, five have issued a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Boston Scientific currently has an average rating of “Buy” and an average price target of $31.00.

Several institutional investors have recently made changes to their positions in the company. Krilogy Financial LLC increased its position in shares of Boston Scientific by 5.9% during the 2nd quarter. Krilogy Financial LLC now owns 7,680 shares of the medical equipment provider’s stock valued at $213,000 after purchasing an additional 430 shares during the last quarter. Sentry Investment Management LLC increased its position in shares of Boston Scientific by 1.1% during the 2nd quarter. Sentry Investment Management LLC now owns 107,243 shares of the medical equipment provider’s stock valued at $2,973,000 after purchasing an additional 1,125 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Boston Scientific by 2.7% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 44,496 shares of the medical equipment provider’s stock valued at $1,233,000 after purchasing an additional 1,178 shares during the last quarter. Cornerstone Capital Management Holdings LLC. increased its position in shares of Boston Scientific by 0.7% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 236,479 shares of the medical equipment provider’s stock valued at $6,554,000 after purchasing an additional 1,650 shares during the last quarter. Finally, Nippon Life Insurance Co. boosted its holdings in Boston Scientific by 2.8% during the 3rd quarter. Nippon Life Insurance Co. now owns 62,876 shares of the medical equipment provider’s stock valued at $1,834,000 after acquiring an additional 1,733 shares during the period. Hedge funds and other institutional investors own 90.15% of the company’s stock.

WARNING: This report was first published by Watch List News and is the sole property of of Watch List News. If you are viewing this report on another domain, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/joseph-michael-fitzgerald-sells-85227-shares-of-boston-scientific-corporation-bsx-stock/1853325.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.